Prognostic significance of expression of p53 oncoprotein in primary (stage I-IIIa) non-small cell lung cancer

Anticancer Research

Volumn 23, Issue 2 C, 2003, Pages 1665-1672

  Tan, Dong Feng ^a,d   Li, Qiang ^a   Rammath, Nithya ^a   Beck, Amy ^a   Wiseman, Sam ^a   Anderson, Timothy ^a   Al Salameh, Ahmand ^a   Brooks, John ^b   Bepler, Gerold ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Non small cell lung cancer; p53 oncoprotein; Prognosis

Indexed keywords

MONOCLONAL ANTIBODY; ONCOPROTEIN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037525273     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Greenlee RT, Hill-Harmon BB, Murray T and Thun M: Cancer Statistics, 2001. CA Cancer J Clin 51: 16-36, 2001.
2. Hollstein M, Sindransky D and Vogelstein B: p53 mutations in human cancer. Science 253: 49-53, 1991.
3. Levine AJ: The p53, the cellular gatekeeper for growth and division. Cell 88: 232-331, 1997.
4. Chiba I, Takahashi T, Nau MM, D' Amico D, Cunel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC and Minna JD: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603-1610, 1990.
5. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K and Sekiya T: Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res 52: 4799-4804, 1992.
6. Schiller JH, Adak S, Feins RH et al: Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: A laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 19: 448-457, 2001.
7. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K and Sugimachi K: K-ras and p53 mutaitons are an independent unfavorable prognostic indicator in patients with non-small cell lung cancer. Br J Cancer 75: 1125-1130, 1997.
8. Li FP, Fraurrieni JF Jr, Mulihill JJS, Blattner WA, Dreyfus MG, Tucker MA and Miller RW: A cancer family syndrome in 24 kindreds. Cancer Res 48: 5358-5362, 1988.
9. Mitsudomi T, Oyama T, Kusano T, Osaki T, Makanishi R and Shirakusa T: Mutations of the p53 gene as predicator of poor prognosis inpatients with non-small cell lung cancer. J Natl Cancer Inst 85: 2018-2023, 1993.
10. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Nijmi T, Shimokata K, Yamakawak K, Nakamura Y, Yeda R and Takahashi T: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1-4, 1993.
11. Marchetti A, Muttitta F, Merlo G, Diella F, Pelegrini S, Pepe S, Macchaiarini P, Chela A, Angeletti CA, Callahan R, Bistocchi M and Squartini F: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53: 2846-51, 1993.
12. Carbone DP, Mitsudomi T, Chiba I, Carbone D, D' Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD and Gazdar AF: P53 immunostaining positivity is associated with reduced survival and is imperfectly correlated ith gene mutation in resected non-small cell lung cancer. Chest 106: 3778-818, 1994.
13. Mitsudomi T, Steinberg MM, Nau MM et al: P53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutaitons and clinical features. Oncogene 7: 171-80, 1992.
14. Quinlan DC, Davidson AG, Summers CK, Warden HE and Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831, 1992.
15. Brambila E, Gazzeri S, Moro D, de Fromentel CC, Gouyer V, Jacrot M and Brambilla C: Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143: 199-220, 1993.
16. Ebina M, Steinberg SM, Mulshine JL and Linnoila RI: Relationship of p53 overexpression and upregulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54: 2496-2503, 1994.
17. Passlick B, Izbicki JR, Riethmuller G et al: p53 in non-small cell lung cancer. J Natl Cancer Inst 86: 801-802, 1994.
18. Fujino M, Dosaka-Akita H, Harada M, Hiroumi H, Kinoshita I, Akie K and Kawakami Y: Prognostic significance of p53 and ras p21 expression in non-small-cell lung cancer. Cancer 76: 2457-63, 1995.
19. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee J, Tu N, Hittelman WN and Hong WK: Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 13: 1893-1903, 1995.
20. Kwiatowski DJ, Harpole DH, Godeski J, Herndon JE, Shieh DB, Richards W, Blanco R, Xu HJ, Strauss GM and Sugarbaker DJ: Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 16: 2468-2477, 1998.
21. Geradts J, Fong KM, Zimmerman PV, Maynard R and Minna JD: Correlation of abnormal RB, pi 6 and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5: 791-800, 1999.
22. Hommura F, Dosaka-Akita H, Kinoshita I, Mishina T, Hiroumi H, Ogura S, Katoh H and Kawakami Y: Predictive value of expression of pi 6, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 81: 696-701, 1999.
23. O' Byne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, Andi A, Koukourakis MI, Giatromanolaki A, Gatter K, Harris AL, Waller D and Jones JL: Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 34: 883-89, 2001.
24. Travis WD, Colby TV, Corrin B, Shimosato Y and Brambilla E: Histological Typing of Lung and Pleural Tumors. Third Edition, Springer, 1999.
25. Mountain C: Revisions in the international system for staging lung cancer. Chest 111: 1710-1717, 1997.
26. Rammath N, Hernandez F, Tan DF, Huberman J, Natarajan N, Beck A, Hyland A, Todorov I, Brooks J and Bepler G: MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 19: 4259-4266, 2001.
27. Kaplan EL and Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-81, 1958.
28. Cox DR: Regression models and life tables. J Royal Stat Soc B 34: 187-220, 1972.
29. Dowrakowska D, Gozdz S, Jassem E, Badzio A, Kbierska G, Urbaniak A, Skokowski J, Damps I and Jassem J: Prognostic relevance of proliferating cell nuclear antigen and p53 expression in non-small cell lung cancer. Lung Cancer 35: 35-41, 2002.
30. Selvaggi G, Scagliotti GV, Torri V et al: Her-2/neu overexpression in patients with radically resected non-small cell lung carcinoma. Cancer 94: 2669-74, 2000.
31. Hirvikoski P, Kumpulainen E, Virtaniemi J et al: p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol 15: 3111-3120, 1997.
32. Seshadri R, Leong AS-Y, McCaul et al: Relationship between p53 gene abnormalities and other tumor characteristics in breast-cancer prognosis. Int J Cancer 69: 135-141.
33. Cho U, Gorina S, Jeffrey P et al: Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265: 346-355, 1994.
34. Kastan MB, Radin AI, Kuerbitz SJ et al: Levels of p53 protein increase with maturation in human hematopoietic cells. Cancer Res 51: 4279-4286, 1991.
35. Kastan MB, Onyekwere O, Sidransky D et al: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
36. Ling G, Persson A, Berne B, Uhlen M, Lundeberg J and Ponten F: Persistent p53 mutations in single cells from normal human skin. Am J Pathol 159: 1247-1253, 2001.
37. Levine AJ, Perry ME, Chang A et al: The 1993 Walter Hubert lecture: the role of p53 tumor suppressor gene in tumorigenesis. Br J Cancer 69: 409-416, 1994.
38. Hinds PW, Finlay CA, Quartin RS et al: Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1: 571-580, 1990.